Advancing mRNA-Based In Vivo CAR-T Cell Therapy
- Innovation: Engineering antibody-conjugated LNP deliver mRNA to reprogram immune cells in vivo, bypassing ex vivo manufacturing
- Advantage: Enabling transient, controlled CAR expression with reduced off target toxicity
- Proof of concept: Showcasing pre-clinical efficacy and safety with preliminary human trials results